1. Introduction
===============

The gene expression patterns of tumor-derived cell lines differ greatly, as do their responses to antiproliferative effects of interferons (IFNs). The cause of this variation has been under investigation for more than 40 years, but only basic regulatory mechanisms of interferon signaling are understood today. Small regulatory genome encoded RNAs, such as microRNAs, have recently attracted attention in genomic research. New methods to analyze the levels of these regulatory elements are now commercially available, but the power of these techniques is still discussed extensively. Our study was designed to compare two methods for microRNA detection with respect to usefulness in defined cell culture assays. The experimental design assesses variation between the two cell lines and the treatment effects of IFNα.

A hallmark of the therapeutic activity of type I interferons is the induction of antiproliferative activity mediated by the upregulation of several hundred response genes with pleiotropic functions \[[@B1]\]. These genes can be divided into two major classes based on the kinetic properties of induction \[[@B2]\]. Primary response genes (PRGs) are upregulated within 24 h after the cytokine signal and the secondary response genes (SRGs) are induced following day 1 when the activity of the PRGs decays. In contrast to SRGs, all PRGs studied to date contain bona fide interferon response elements in the promoter region, which are required for binding of the interferon-stimulated gene factor 3 (ISGF3) complex and for janus kinase/signal transducer of transcription (JAK/STAT)-pathway-mediated signaling.

Expression of PRGs is turned off by proteins termed suppressors of cytokine signaling (SOCS) \[[@B3]\]. As the nomenclature indicates, this class of polypeptides has the capacity to interfere and silence other cytokine-induced signaling cascades (for review *see*\[[@B4]\]). SOCS1 for instance is part of the early inducible PRG cluster and down modulation occurs together with the other genes before onset of SRG expression. It is believed that feedback inhibition of JAK/STAT signaling by SOCS1 represses transcriptome modulation of IFNα signaling \[[@B5]\]. Regulation of SOCS protein translation by interferon-regulated microRNAs (IRmiRs) would enhance the potential of cytokine fine regulation. It has been reported that miR-19 antagonists lead to higher SOCS1 levels and miR-19 mimics can repress SOCS1 reporter constructs, thus obviously supporting the bioinformatic predictions that SOCS1 is a direct target of miR-19 \[[@B6]\]. Inhibition of SOCS activity could for instance prolong the duration of cytokine activity, which has obvious clinical implications.

Following the discovery of microRNAs in virtually all higher eukaryotic organisms significant research efforts were initiated to address the function of these catalytic oligonucleotides which are the natural counterparts of synthetic small inhibitory RNAs (siRNAs) used for experimental gene silencing (for review *see*\[[@B7]\]). MicroRNAs are positive and negative modulators of the expression of entire gene clusters that contain complementary microRNA recognition sequence motifs in the 3\'-UTR. Today, prediction of microRNA target genes by homology-based algorithms is still ambiguous \[[@B8]\]. The activity of one or several microRNAs could explain suppression of the entire PRG cluster provided that microRNA abundance is regulated by IFNα. Alternatively, microRNA-mediated degradation of transcripts encoding negative regulatory proteins would also abolish PRG expression and restore IFNα responsiveness.

Some recent reports showed that interferon beta (IFNβ) stimulation can boost microRNA levels in cell culture together with inhibition of viral replication \[[@B9]\]. At this point it is an open question whether this induction is IFNβ specific or a shared feature of all type I interferons. To investigate whether microRNA are also involved in regulation of IFNα response, we used two human-tumor-derived cell lines: the melanoma line ME-15 \[[@B10]\] and the hepatoma line HuH7 \[[@B11]\]. We have chosen these cell lines as models, because we have a good understanding of the IFNα responses at the mRNA and the protein levels in these cell lines. Further we chose to use a melanoma cell line because IFN is also used for treatment of this cancer type. HuH7 is commonly used as a model for testing antiviral effects of IFN in the HCV replicon system. In both models efficient responses to IFNα have been shown at the functional and transcriptional level. IFNα response genes carry response elements in their promoter region and these motifs are responsible for gene expression with similar efficiency in many cell types. Therefore we expected to find a similar regulated set of genes in both lines given that IRmiR genes are regulated by the same mechanism, whereas some constitutively expressed microRNA genes were expected to be cell type specific for functional reasons. We have chosen a DNA-microarray-based technology (Illumina) for the multi-parallel expression analysis of all known human microRNAs (<http://microrna.sanger.ac.uk/>; Release 10.0: August 2007). This method allowed us to process total RNA as template, allowing the possibility of mRNA gene expression profiling in further experiments. Briefly, annealing of microRNA specific primers combined with enzymatic polyadenylation allows multi-parallel polymerase chain reaction (PCR)-mediated amplification of individual microRNAs. The output of this step is a DNA amplicon library that reflects to a large extent the original stoichiometry of mature microRNAs in a cell or tissue \[[@B12]\]. PCR amplification is performed with fluorescently labeled primers, which allows quantitative signal detection by conventional confocal laser scanning.

2. Materials and Methods
========================

2.1. Cell Culture, Interferon Treatment, and RNA Precipitation
--------------------------------------------------------------

Melanoma cells (ME-15) were cultured in RPMI 1640 with L-Glutamine supplemented with non-essential amino acids and sodium pyruvate (1 mM) and hepatoma (HuH7) cells were cultured in DMEM + GlutaMAX. Both media contained 10% FBS. All cell culture reagents were purchased from Invitrogen (GIBCO^®^). Roferon (Interferon alpha2a, ROCHE) was diluted in fresh medium to a final concentration of 1,000 U/mL and control cultures were grown without cytokine. Cells were cultured at 37°C in a humidified atmosphere containing 5% CO~2~. Total RNA preparation was carried out using TRIZOL (Invitrogen) total RNA extraction using 1/2 volume of 1-bromo-3-chloro-propane (molecular biology grade, SIGMA) as chloroform substitute. For efficient recovery of small RNAs, DNA LoBind tubes (Eppendorf) were used and all centrifugation steps were performed at maximum speed and 4°C in an Eppendorf 5417R centrifuge. Total RNA was precipitated with 2 vol of 2-propanol (Fluka) at -20°C for at least 16 h. The RNA pellet was washed with 75% ethanol (Merck), dried, and dissolved in DEPC-treated water (Ambion). The RNA was quantified with Quant-iT™ RiboGreen^®^ RNA Assay (Invitrogen) as suggested by Illumina.

2.2. Illumina Bead Array MicroRNA Detection
-------------------------------------------

Starting with 500 ng/sample of total RNA, mature microRNAs were amplified with the Illumina human v1 MicroRNA expression profiling kit containing primers for 743 human microRNAs. The resulting amplicons were hybridized to a 96 sample universal probe capture array and fluorescent signals were detected by confocal laser scanning. All steps were performed according to Illumina\'s instructions manual.

2.3. Data Processing and Statistical Analysis
---------------------------------------------

The data was processed with Beadstudio software (version 3.1.3, gene expression module 3.3.8) including the calculation of detection *p* values based on negative control bead signals. Log-transformation, loess normalization \[[@B13]\] and statistical analysis were performed with R (2.8.1) \[[@B14]\] using the package lumi (1.8.3) \[[@B15]\] and software contained therein, in particular limma (2.16.4) \[[@B16]\]. Statistical models were chosen as follows: a linear model (limma *t* statistics) with two separate coefficients for HuH7 and ME-15 cells was used for the selection of differently expressed genes shown in Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}. Statistics represented in the tables were calculated by testing the two indicated conditions as independent factors. In Table [1](#T1){ref-type="table"}, *p* values were adjusted by the false discovery rate method \[[@B17]\]. Treatment effects shown in Table [2b](#T2){ref-type="table"} and Figure [3a](#F3){ref-type="fig"} were modeled with two coefficients (cell line, treatment) for time point 4 h, *p* values arise from *t* statistics. Normalized relative fluorescence levels were calculated by 2\^mean (of log2 transformed, loess normalized values). Change factors (CHF) were calculated as fold change on the linear scale minus 1 as previously described \[[@B2]\]. Raw data, non-normalized, and normalized microRNA expression data have been submitted to the Gene Expression Omnibus with accession number GSE16421.

![**Differential microRNA expression in human melanoma (ME-15) and hepatoma (HuH7) cells**. microRNA expression levels were compared in two cell lines at two different time points and corrected for the treatment effect. The 50 most significant (*p* value below 10^-12^) microRNA expression values from untreated samples are shown in a heat diagram including hybridization controls as reference for technical variance. *White* indicates noise levels, *yellow* indicates the first quartile, *orange* the median, *red* the third quartile, and *black* maximum expression levels. The intensity data, significance values and the IFNα-dependent expression levels are summarized in Table 1.](1480-9222-11-1-9012-1){#F1}

###### 

Cell line differences in microRNA expression

                                    Control   Interferon-alpha treated                                                                                                      
  --------------------------------- --------- -------------------------- -------------- -------- -------- -------------- -------- -------- -------------- -------- -------- --------------
  microRNAs rated higher in HuH7                                                                                                                                            
  hsa-miR-122a                      685       30,912                     44.14\*\*\*    704      32,058   44.51\*\*\*    717      30,459   41.46\*\*\*    876      29,044   32.17\*\*\*
  hsa-miR-224                       359       10,085                     27.07\*\*\*    345      7,358    20.31\*\*\*    358      8,183    21.87\*\*\*    333      7,483    21.44\*\*\*
  hsa-miR-483                       915       23,671                     24.87\*\*\*    811      18,073   21.29\*\*\*    849      17,784   19.95\*\*\*    802      17,554   20.88\*\*\*
  hsa-miR-200a                      517       8,392                      15.22\*\*\*    667      13,543   19.29\*\*\*    722      11,317   14.68\*\*\*    500      12,649   24.30\*\*\*
  hsa-miR-218                       405       5,654                      12.96\*\*\*    417      6,527    14.64\*\*\*    419      5,764    12.76\*\*\*    431      6,155    13.29\*\*\*
  hsa-miR-618                       700       7,549                      9.78\*\*\*     649      8,128    11.52\*\*\*    651      8,042    11.35\*\*\*    616      7,416    11.03\*\*\*
  hsa-miR-215                       638       6,826                      9.71\*\*\*     829      6,013    6.25\*\*\*     663      6,641    9.02\*\*\*     723      6,501    7.99\*\*\*
  hsa-miR-192                       3,956     34,724                     7.78\*\*\*     3,401    34,181   9.05\*\*\*     4,021    29,382   6.31\*\*\*     3,343    33,293   8.96\*\*\*
  hsa-miR-194                       4,410     32,950                     6.47\*\*\*     4,142    32,991   6.96\*\*\*     4,700    33,182   6.06\*\*\*     4,410    32,422   6.35\*\*\*
  hsa-miR-182                       1,575     11,480                     6.29 \*\*\*    2,541    13,088   4.15\*\*\*     2,227    12,512   4.62\*\*\*     3,067    13,907   3.53\*\*\*
  hsa-miR-452                       434       2,284                      4.27\*\*\*     707      3,326    3.70\*\*\*     530      3,378    5.37\*\*\*     636      3,028    3.76\*\*\*
  hsa-miR-183                       1,763     8,748                      3.96\*\*\*     2,123    8,945    3.21\*\*\*     2,000    8,984    3.49\*\*\*     2,129    8,258    2.88\*\*\*
  hsa-miR-200b                      1,934     7,551                      2.90\*\*\*     1,692    9,633    4.69\*\*\*     1,705    9,393    4.51\*\*\*     1,911    10,855   4.68\*\*\*
  hsa-miR-143                       1,355     5,087                      2.75\*\*\*     1,775    7,167    3.04\*\*\*     1,698    5,688    2.35\*\*\*     1,765    7,519    3.26\*\*\*
  hsa-miR-624                       4,852     13,418                     1.77\*\*       4,188    11,593   1.77\*\*\*     4,479    11,718   1.62\*\*       3,872    10,539   1.72\*\*
  hsa-miR-99a                       8,653     20,232                     1.34\*\*       8,887    20,645   1.32\*\*\*     9,064    18,019   0.99\*\*       8,870    19,506   1.20\*\*
  hsa-miR-27b                       10,067    22,544                     1.24\*\*       11,924   23,914   1.01\*\*\*     11,564   23,044   0.99\*\*\*     12,182   24,515   1.01\*\*
  microRNAs rated higher in ME-15                                                                                                                                           
  hsa-miR-146a                      36,976    15,721                     -1.35\*\*      33,410   16,103   -1.07\*\*\*    35,166   15,137   -1.32\*\*\*    35,688   19,962   -0.79\*\*\*
  hsa-miR-422b                      19,264    7,759                      -1.48\*\*      19,962   7,832    -1.55\*\*\*    20,641   7,462    -1.77\*\*\*    17,453   7,152    -1.44\*\*\*
  hsa-miR-149                       5,868     2,246                      -1.61\*\*      6,195    2,030    -2.05\*\*\*    6,061    1,743    -2.48\*\*\*    5,477    2,418    -1.26\*\*
  hsa-miR-510                       1,051     368                        -1.86\*\*\*    1,489    396      -2.76\*\*\*    1,435    366      -2.92\*\*\*    1,053    384      -1.74\*\*\*
  hsa-miR-30a-5p                    10,664    3,717                      -1.87\*\*      10,223   3,700    -1.76\*\*\*    10,686   3,477    -2.07\*\*\*    10,466   4,538    -1.31\*\*\*
  HS_98                             3,274     1,065                      -2.08\*\*      3,225    859      -2.76\*\*\*    3,445    965      -2.57\*\*\*    2,850    750      -2.80\*\*\*
  hsa-miR-340                       4,583     1,443                      -2.18\*\*      4,218    1,220    -2.46\*\*\*    4,664    1,061    -3.40\*\*\*    3,078    933      -2.30\*\*\*
  HS_182.1                          1,965     615                        -2.2\*\*       1,687    606      -1.79\*\*      1,903    562      -2.39\*\*\*    1,844    534      -2.45\*\*\*
  hsa-miR-378                       4,619     1,371                      -2.37\*\*      4,975    1,364    -2.65\*\*\*    4,994    1,213    -3.12\*\*\*    4,188    1,237    -2.38\*\*\*
  HS_305_b                          4,105     1,207                      -2.40\*        3,853    833      -3.63\*\*\*    4,278    977      -3.38\*\*\*    3,688    1,076    -2.43\*\*\*
  hsa-miR-505                       1,312     343                        -2.83\*\*\*    2,070    342      -5.05\*\*\*    2,050    360      -4.70\*\*\*    2,030    362      -4.60\*\*\*
  hsa-miR-10a                       1,570     350                        -3.48\*\*      1,592    350      -3.55\*\*\*    1,828    360      -4.07\*\*\*    1,880    352      -4.34\*\*\*
  hsa-miR-10b                       1,695     378                        -3.49\*\*      2,929    371      -6.89\*\*\*    3,564    411      -7.67\*\*\*    4,297    382      -10.26\*\*\*
  hsa-let-7g                        10,720    2,302                      -3.66\*\*      16,046   3,077    -4.21\*\*\*    13,792   2,854    -3.83\*\*\*    15,435   2,568    -5.01\*\*\*
  hsa-miR-584                       11,643    2,261                      -4.15\*\*\*    12,717   1,873    -5.79\*\*\*    12,394   1,912    -5.48\*\*\*    12,616   1,674    -6.54\*\*\*
  hsa-let-7i                        11,701    2,255                      -4.19\*\*      16,410   2,707    -5.06\*\*\*    15,319   2,251    -5.80\*\*\*    15,718   2,563    -5.13\*\*\*
  hsa-miR-330                       9,029     1,653                      -4.46\*\*\*    9,684    1,670    -4.80\*\*\*    9,432    1,397    -5.75\*\*\*    7,773    1,380    -4.63\*\*\*
  HS_307_b                          2,453     444                        -4.52\*\*\*    4,188    443      -8.45\*\*\*    3,669    407      -8.01\*\*\*    3,318    448      -6.41\*\*\*
  hsa-miR-34c                       2,292     412                        -4.56\*\*      3,303    426      -6.75\*\*\*    3,524    381      -8.25\*\*\*    2,403    404      -4.95\*\*
  hsa-miR-133a                      9,270     1,594                      -4.82\*\*\*    7,942    1,662    -3.78\*\*\*    8,488    1,435    -4.92\*\*\*    6,495    1,783    -2.64\*\*\*
  hsa-miR-361                       5,234     828                        -5.32\*\*\*    7,641    755      -9.13\*\*\*    7,356    875      -7.41\*\*\*    7,904    706      -10.19\*\*\*
  hsa-miR-508                       2,552     325                        -6.86\*\*      4,280    376      -10.39\*\*\*   3,965    357      -10.09\*\*\*   4,013    336      -10.96\*\*\*
  hsa-miR-9\*                       8,372     1,039                      -7.06\*\*\*    10,114   940      -9.76\*\*\*    10,027   1,263    -6.94\*\*\*    9,948    843      -10.81\*\*\*
  hsa-miR-31                        5,967     661                        -8.03\*\*\*    5,742    720      -6.97\*\*\*    6,619    657      -9.07\*\*\*    5,978    728      -7.21\*\*\*
  hsa-miR-506                       5,855     625                        -8.37\*\*\*    6,125    713      -7.59\*\*\*    5,916    665      -7.90\*\*\*    5,602    675      -7.30\*\*\*
  hsa-miR-211                       5,147     476                        -9.81\*\*\*    3,218    490      -5.57\*\*\*    3,833    471      -7.14\*\*      5,575    464      -11.01\*\*\*
  hsa-miR-296                       6,194     570                        -9.86\*\*\*    5,913    504      -10.72\*\*\*   6,441    557      -10.57\*\*\*   4,369    532      -7.21\*\*\*
  hsa-miR-598                       4,445     401                        -10.09\*\*\*   4,475    386      -10.59\*\*\*   4,934    424      -10.63\*\*\*   4,127    367      -10.24\*\*\*
  hsa-miR-199b                      9,081     775                        -10.71\*\*\*   9,478    916      -9.35\*\*\*    9,629    865      -10.13\*\*\*   8,059    911      -7.85\*\*\*
  hsa-let-7b                        8,236     539                        -14.28\*\*\*   12,563   475      -25.44\*\*\*   12,150   500      -23.30\*\*\*   12,309   452      -26.24\*\*\*
  hsa-miR-509                       10,413    536                        -18.44\*\*\*   10,346   512      -19.22\*\*\*   9,966    548      -17.20\*\*\*   9,311    529      -16.62\*\*\*
  hsa-miR-9                         12,587    422                        -28.85\*\*\*   15,870   447      -34.50\*\*\*   15,502   418      -36.09\*\*\*   16,402   429      -37.26\*\*\*
  hsa-miR-514                       12,065    364                        -32.16\*\*\*   13,112   358      -35.64\*\*\*   12,201   315      -37.74\*\*\*   12,355   355      -33.83\*\*\*
  Hybdridization controls                                                                                                                                                   
  array_hyb_con4                    6,404     7,110                      0.11           7,724    6,684    -0.16          7,031    6,739    -0.04          6,964    6,746    -0.03
  array_hyb_con3                    6,923     7,681                      0.11           7,833    7,368    -0.06          7,422    7,054    -0.05          6,906    7,365    0.07
  array_hyb_con1                    10,779    11,868                     0.10           11,812   11,728   -0.0.01        11,436   11,382   0.00           11,059   11,522   0.04
  array_hyb_con2                    10,258    11,145                     0.09           11,382   10,829   -0.05          11,075   10,650   -0.04          9,997    10,283   0.03

List of calculated relative fluorescent levels (without background correction) and calculated differences (CHF) between hepatoma (HuH7) and melanoma (ME-15) cells. A linear model with ME-15 and HuH7 as separate factors was used to estimate cell line differences in microRNA expression. The genes with the highest significance (and log factor change \>0.5) are listed in the upper section and the bottom shows data for the hybridization controls as reference. Change factors show the cell line differences of the retransformed mean to the linear scale. *p* values (limma *t* test) were adjusted by false discovery rate correction. Significance codes are defined by the intervals: \'\*\*\*\' \< 0.001 ≤ \'\*\*\' \< 0.01 ≤ \'\*\' \< 0.05

###### 

Modulation of microRNA expression by IFNα---4 and 24 h after stimulation

                                   Control   Interferon-alpha treated                                                                                                        
  -------------------------------- --------- -------------------------- -------------- -------- --------- -------------- -------- -------- --------------- -------- -------- --------------
  Validated microRNAs                                                                                                                                                        
  hsa-miR-19a                      13,617    6,726                      -1.02          18,318   17,178    -0.07          19,226   17,409   -0.10           14,425   14,079   -0.02
  hsa-miR-19b                      13,365    9,406                      -0.42          25,463   22,438    -0.13          21,532   20,625   -0.04           18,039   17,440   -0.03
  hsa-miR-30e-5p                   9,497     6,838                      -0.39          13,045   11,321    -0.15          12,643   10,887   -0.16           13,230   11,809   -0.12
  hsa-let-7a                       15,244    4,335                      -2.52.         28,304   6,181     -3.58 \*\*\*   22,226   6,386    -2.48\*\*\*     30,449   5,612    -4.43\*\*\*
  hsa-let-7b                       8,236     539                        -14.28\*\*\*   12,563   475       -25.44\*\*\*   12,150   500      -23.30 \*\*\*   12,309   452      -26.24\*\*\*
  hsa-miR-203                      907       325                        -1.79\*\*      1,155    348       2.32\*\*\*     1,302    359      -2.63\*\*\*     1,186    5,757    -1.07\*\*
  hsa-miR-130b                     5,700     8,316                      -0.46          13,023   13,880    0.07           9,994    14,055   0.41            12,053   12,432   0.03
  hsa-miR-455                      2,677     2,604                      -0.03          3,944    5,285     0.34\*         3,437    5,927    0.72\*\*        3,262    5,342    0.64\*
  b                                ME-15     HuH7                                                                                                                            
                                   4 h       24 h                       4 h            24 h                                                                                  
                                   -IFNa     +IFNa                      CHF            -IFNa    +IFNa     CHF            -IFNa    +IFNa    CHF             -IFNa    +IFNa    CHF
  Interferon-regulated microRNAs                                                                                                                                             
  hsa-miR-33b                      1,226     3,484                      1.84\*\*       2,888    2,318     -0.25          476      1,113    1.34\*\*        1,306    1,851    0.42\*\*\*
  hsa-miR-33                       2,631     7,352                      1.79           9,774    5,764     -0.70\*        1,887    6,645    2.52.           8,893    2,726    -2.26
  hsa-miR-126\*                    2,221     5,409                      1.44\*         5,578    6,111     0.10           4,749    6,410    0.35.           5,687    5,803    0.02\*\*\*
  hsa-miR-10b                      1,695     3,564                      1.10\*         2,929    4,297     0.47\*\*       378      411      0.09            371      382      0.03
  hsa-miR-551b                     2,085     4,169                      1.00\*         4,423    3,419     -0.29          1,804    4,979    1.76\*          5,221    4,865    -0.07
  hsa-miR-137                      1,037     1,966                      0.90           2,523    2,872     0.14           1,613    3,155    0.96\*\*        3,429    3,598    0.05
  hsa-miR-138                      2,158     4,074                      0.89\*         4,709    3,701     -0.27          725      828      0.14            903      859      -0.05
  hsa-miR-130b                     5,700     9,994                      0.75           13,023   12,053    -0.08          8,316    14,055   0.69\*\*        13,880   12,432   -0.12
  hsa-miR-101                      6,701     11,387                     0.70           13,088   11,688    -0.12          3,569    10,871   2.05\*\*        10,445   10,796   0.03
  hsa-miR-140                      7,339     12,236                     0.67           15,512   15,931    0.03           3,058    5,976    0.95\*          6,135    7,221    0.18
  HS_92                            829       1,356                      0.64.          1,246    1,179     -0.06          407      587      0.44            492      478      -0.03
  hsa-miR-362                      1,382     2,234                      0.62\*         2,144    2,276     0.06           1,907    2,737    0.43\*          2,456    2,519    0.03
  hsa-miR-19b                      13,365    21,532                     0.61\*\*       25,463   18,039    -0.41          9,406    20,625   1.19\*          22,438   17,440   -0.29
  hsa-miR-130a                     13,031    20,878                     0.60.          27,571   23,048    -0.20          17,884   31,012   0.73\*          33,801   28,875   -0.17
  hsa-miR-579                      552       816                        0.48.          992      1,053     0.06           729      1,362    0.87\*          1,250    1,308    0.05
  hsa-miR-29b                      23,138    34,148                     0.48.          32,691   29,710    -0.10          8,737    17,989   1.06\*          20,599   17,405   -0.18.
  hsa-miR-19a                      13,617    19,226                     0.41\*         18,318   14,425    -0.27          6,726    17,409   1.59.           17,178   14,079   -0.22.
  hsa-miR-338                      1,298     1,813                      0.40.          1,870    1,603     -0.17          2,363    4,603    0.95.           5,109    4,088    -0.25
  hsa-miR-590                      1,403     1,949                      0.39.          1,545    1,367     -0.13          669      1,068    0.60.           884      847      -0.04
  hsa-miR-545                      1,455     1,973                      0.36.          2,149    1,720     -0.25\*        829      1,371    0.65\*\*        1,573    1,393    -0.13
  hsa-miR-30e-5p                   9,497     12,643                     0.33           13,045   132,030   0.01           6,838    10,887   0.59\*          11,321   11,809   0.04
  hsa-miR-570                      1,989     2,576                      0.30.          2,397    2,610     0.09           2,213    3,739    0.69\*          4,312    3,708    -0.16
  hsa-miR-301                      13,621    17,531                     0.29\*         16,321   15,142    -0.08          5,646    10,460   0.85\*          10,925   10,295   -0.06.
  hsa-miR-561                      517       621                        0.20           568      464       -0.22\*\*      683      1,157    0.69\*\*        1,149    941      -0.22
  HS_250                           4,284     1,813                      -1.36.         740      983       0.33           3,688    2,337    -0.58           1,195    1,303    0.09
  c                                ME-15     HuH7                                                                                                                            
                                   4 h       24 h                       4 h            24 h                                                                                  
                                   -IFNa     +IFNa                      CHF            -IFNa    +IFNa     CHF            -IFNa    +IFNa    CHF             -IFNa    +IFNa    CHF
  Validated microRNAs                                                                                                                                                        
  hsa-miR-19a                      13,617    19,226                     0.41\*         18,318   14,425    -0.27          6,726    17,409   1.59.           17,178   14,079   -0.22
  hsa-miR-19b                      13,365    21,532                     0.61\*\*       25,463   18,039    -0.41          9,406    20,625   1.19\*          22,438   17,440   -0.29.
  hsa-miR-30e-5p                   9,497     12,643                     0.33           13,045   13,230    0.01           6,838    10,887   0.59\*          11,321   11,809   0.04
  hsa-let-7a                       15,244    22,226                     0.46           28,304   30,449    0.08           4,335    6,386    0.47.           6,181    5,612    -0.10
  hsa-let-7b                       8,236     12,150                     0.48\*         12,563   2,309     -0.02          539      500      -0.08           475      452      -0.05
  hsa-miR-203                      907       1,302                      0.44\*         1,155    1,186     0.03           325      359      0.10            348      575      0.665\*\*

Microarray data for RT-PCR validated microRNAs, *see* description of Table 1. Average relative fluorescent levels and their change factors (CHFs) are shown for hepatoma (HuH7) and melanoma (ME-15) cells at two time points. Genes were selected by significance calculated in a linear model with interaction assuming that the change may not occur in both cell lines (e.g. miR-10b has no detectable levels in HuH7). *p* value significance codes are defined by the intervals: \'\*\*\*\' \< 0.001 ≤ \'\*\*\' \< 0.01 ≤ \'\*\' \< 0.05 ≤ \'.\' \< 0.1. Section c shows the microarray expression levels of microRNAs assayed by RT-PCR (treatment analysis)

![**IFNα-dependent modulation of microRNA expression**. **a** Volcano plot display of IFNα induced microRNA upregulation 4 h after induction. The change factor values (2\^log factor change -1) are plotted on the *X*-axis against the *p* value in logarithmic scale on the *Y*-axis. Top-rated microRNAs are annotated together with the let-7 family members. **b** Confirmation of IFNα effect for selected microarray data by qPCR. The CT-values are the average of three technical and three biological replicates and changes were calculated with 2\^ΔMNE (mean normalized expression values). *Error bars* show 2\^ΔMNE ± Δ*x* (average standard error of treated and untreated MNE) from biological triplicates. miR-30e failed to amplify in ME-15 and miR-203 was below the detection limit in HuH7. Expression values were normalized against endogenous snoRNA RNU48 levels.](1480-9222-11-1-9012-3){#F3}

2.4. Quantitative PCR and Data Processing
-----------------------------------------

microRNA levels were measured using TaqMan^®^ microRNA assays (Applied Biosystems) using the TaqMan^®^ MicroRNA reverse transcription (RT) kit with TaqMan^®^ 2× universal PCR master mix (No AmpErase^®^ UNG) as recommended by the supplier. Ten nanograms of total RNA was used as input for amplification using the samples used for microarray analysis. Reversed transcriptase products were diluted 1:15 and measured on an ABI 7900HT fast real-time PCR system. Technical replicates were run on three different plates (one with 40 cycles and two with 50 cycles) and threshold for cycling time (CT) calculation was set for all probes to 0.2. For estimation of endogenous small RNA content, the nucleolar RNA RNU48 was used as control and reference.

Standard error (Δ*x*) was calculated by the average standard error of treated and untreated MNE for biological replicates.

3. Results and Discussion
=========================

The following technical aspects have to be considered for result interpretation. The dataset of the microRNA bead array assay is not directly comparable to gene expression arrays where in vitro translated transcripts are directly hybridized to the probes. Moreover Illumina\'s bead array technology tends to have higher background fluorescence levels and lower change factor values than Genechips from Affymetrix. Background (average of negative control signals) and noise (standard deviation of negative probes from each sample) were 528 ± 60 and 229 ± 67, respectively. The density of all samples shows a bimodal distribution peaking around the background fluorescent levels and the robust levels (approximately 12,000). The curve is skewed to the right and peak density height is found in the ratio 4:1 considering all probes (data not shown). The distribution of probes detected in all samples (detection *p* value threshold at 0.01) has a plateau ranging from about 2,000 close to the detectors maximum capacity of 2\^16 relative fluorescent units \[[@B12]\]. As expected, the correlation of data coming from biological replicates *r*^2^ = 0.952 ± 0.028 (not normalized) and *r*^2^ = 0.956 ± 0.022 (after loess normalization and log-transformation) was lower than for technical replicates *r*^2^ \> 0.97 \[[@B12]\]. We preferred loess normalization to quantile normalization because the later was too aggressive for the given small probe numbers.

As a first step we wished to address the robustness of the microRNA array in probe detection by selecting microRNA genes that are detected under all experimental conditions with high statistical significance in all biological triplicates (detection *p* value \< 0.01). In each set of triplicate samples (control, 4 h or 24 h, IFNα stimulation) we detect approximately 270 genes that fulfill the above criteria. This corresponds to roughly a third of microRNAs available for detection in the assay system. Furthermore, this result suggests indirectly that IFNα treatment does not induce global changes in microRNA gene expression, but it modulates rather the expression of individual genes.

Today it is well established that microRNA expression patterns are cell and tissue type specific, which is consistent with a role in cell differentiation and biological function \[[@B8]\]. Thus we expected to detect genes with preferential expression in either hepatoma or melanoma cells as these cell lines are derived from different tumors. Indeed, when all experimental conditions and data points are included in the data analysis about 150 microRNAs genes show preferential expression in either HuH7 or ME-15 cells (Figure [1](#F1){ref-type="fig"}). Table [1](#T1){ref-type="table"} shows the expression data for the most significant genes including change factors and significance score as reference. Among these differentially expressed genes there are three members of the let-7 family, which has properties of tumor suppressor genes (for review *see*\[[@B18]\]). Therefore it is not surprising that the members of this well-known microRNA gene family are deregulated in the analyzed cancer cells too. Furthermore, the different developmental stage of our cancer cell lines is expected to have left a genomic fingerprint where some microRNA genes are expressed in one but not the other cell line \[[@B19]\]. Consistent with this, expression of some microRNAs is strictly cell type specific and barely detectable in the other cell type (Figure [2a](#F2){ref-type="fig"}), for example the liver-specific miR-122a and miR-192 \[[@B20]\].

![**Cell line specific microRNA expression Volcano plot (**a**) display demonstrates the multi-variant biological diversity of microRNA expression in ME-15 or HuH7 cells**. The estimated fold-change value (change factor) is plotted on the *X*-axis against the *p* value (limma *t* statistics) in logarithmic scale on the *Y*-axis. A linear model, using the expression values of untreated ME-15 cells at 4 h as base together with three parameters to estimate differences in time, treatment, or cell line. The top ranked and qPCR measured microRNAs are annotated. **b** Quantitative PCR validation of microarray data using eight selected microRNAs. Input total RNA came from independent cell cultures. Data are shown as relative cycling times (ΔCT) calculated with endogenous control RNU18 for ME-15 (*color-filled bars*) and HuH7 (*gray*). *Error bars* represent ΔCT ± Δ*x* (standard deviation of biological replicates). ΔΔCT are noted above the bars together with the significance codes for *t* statistics defined by the intervals \'\*\*\*\' \< 0.001 ≤ \'\*\*\' \< 0.01 ≤ \'\*\' \< 0.05 ≤ \'.\' \< 0.1.](1480-9222-11-1-9012-2){#F2}

Bead-array-based microRNA detection technology, including the bio-statistic analysis, is currently not well established or widely used and we have applied a commercial PCR-based assay to confirm the array data for some microRNAs that cover different expression levels and change factors. In contrast to mRNA profiling, where RT-PCR-based assays are considered as gold standard for data validation, new generation deep sequencing is considered as the method of choice for microRNA quantification but is not available in our research institute. For the microRNAs let-7 a/b, miR-19 a/b, and miR-203, the PCR-based quantification method (Figure [2b](#F2){ref-type="fig"}) confirmed the direction of change found with microarray technology (Table [2a](#T2){ref-type="table"}). Expression of miR-130b and miR-455 was at similar levels in both assays. The correlation calculated for the eight tested microRNAs was acceptable: multiple *r*^2^ from *f* test of mean relative cycling times (ΔCT) to mean log2 microarray expression values was 0.9279. Differences of absolute levels between the microRNA targets probably results from different hybridization properties of the microarray probes and variation in the performance of Taqman primers for the specific microRNA on the other side.

Assuming that any IFNα relevant microRNA will have the same kinetics as the mRNA for PRGs, we looked at the regulation of microRNA genes in our experiment. These IRmiRs should respond to IFNα stimulation preferentially in both cell lines, because this would be a good indication of a general mechanism in the IFNα response. Within the 25 most significantly regulated genes (Table [2b](#T2){ref-type="table"}), only one gene (HS_250) is downregulated. A general upregulation of transcripts is consistent with classic IFNα signaling seen for mRNAs. However, the maximal observed change factor with high significance was 1.84 (miR-33b in Table [2b](#T2){ref-type="table"}) which is clearly lower than the values seen for protein coding mRNAs \[[@B2]\]. We also included an expression analysis 24 h after IFNα stimulation in order to detect microRNA genes that show either delayed induction or remain activated at comparable levels to the 4 h stimulus. Based on our data set, the majority of the microRNA response genes show no further induction, but rather moderate downregulation 24 h after induction. This finding is not surprising as we expected immediate early impact of IFNα-mediated primary signaling.

We also measured the IFNα response in the same experiment and for the same microRNAs (Table [2c](#T2){ref-type="table"}). When we analyze the IFNα effect at the early time point in both cell lines we find all the validated microRNAs to be upregulated (Figure [3a](#F3){ref-type="fig"}). The magnitude of upregulation and the basal expression levels of the microRNA-19a and 19b are similar in both cell lines (Figure [3b](#F3){ref-type="fig"}, top). This and the finding that miR-19 regulates SOCS1 \[[@B4]\] may be relevant for the regulation of cytokine signaling. let-7a and let-7b had higher levels in the melanoma-cell-line-derived samples compared HuH7, but the induction by IFNα in ME-15 could not be reproduced by RT-PCR (Figure [3b](#F3){ref-type="fig"}, bottom). In both assays accurate fold changes are difficult to calculate, if the baseline expression level is close to background noise or the detection limit. An example of a gene at the detection limit is miR-203, which is not detectable without IFNα treatment in HuH7 cells (Table [2c](#T2){ref-type="table"}). Upon IFNα stimulation (24 h in HuH7) the microRNA is detectable above background suggesting minimal induction. Consequently a solid change factor cannot be calculated, which is consistent with the high variance obtained by qPCR (ME-15). This result is in fact not surprising, because both technologies rely on logarithmic PCR amplification of microRNA templates. At low expression levels, both technologies show relatively high variation in biological replicates, which should be considered for data interpretation. Interestingly, miR-203 has a putative binding site for ISGF3 in the promoter region, which would enable IFNα-dependent upregulation. miR-30 has been reported to be IFNβ inducible, although the subclass measured was not specified by the authors \[[@B9]\]. We decided to analyze the most promising candidate (miR-30e-5p) present in our microarray dataset (Figure [3a](#F3){ref-type="fig"} in gray). Detection of miR-30e failed in ME-15 cells due to technical problems, but induction in HuH7 was similar to miR-19a/b.

Some technology-related questions remain open. The microRNA assay measures essentially the number of amplicons generated by RT-PCR for each transcript. Thus the signal is an indirect measurement of transcript abundance as compared to classical mRNA microarray platforms, where the target mRNA is directly labeled during linear amplification by in vitro transcription. As a consequence, change factor calculations for amplicon-based assays are ambiguous.

In summary, Illumina\'s bead array technology is well suited for multi-parallel profiling of microRNAs expressed in different cell types or tissues. We were also able to detect IFNα-inducible microRNA genes although the changes observed were moderate and biological significance remains to be proven. Like most microarray-based detection technologies the technical variability among identical samples is low compared to biological variations of individual cell cultures. At this point it is important to note that variation among biological samples occurs and is independent of the parameters that are measured. Consistent with IFNα-dependent induction of mRNAs we find that virtually all modulated microRNA genes are upregulated. However, the IFNα-induced changes detected in our study are relatively small compared to the changes induced by IFNβ in HuH7 cells \[[@B9]\]. Finally, it is noteworthy that IRmiRs have similar kinetic properties to their mRNA counterparts. miR-10b for instance is induced early in ME-15 and remains upregulated, while miR-19 abundance ceases after 24 h. In general, the majority of IRmiR genes were reset to basal levels after 24 h and further studies are needed for kinetic classification. Thus, our study adds another level of complexity to the dynamic regulation IFNα signaling and other mechanisms like epigenetic promoter methylation are currently under intense investigation in our laboratories.
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